Objective: Analysis of steroids by gas chromatography-mass spectrometry (GC-MS) defines a subject's steroidal fingerprint. Here, we compare the steroidal fingerprints of obese children with or without liver disease to identify the 'steroid metabolomic signature' of childhood nonalcoholic fatty liver disease. Methods: Urinary samples of 85 children aged 8.5-18.0 years with BMI >97% were quantified for 31 steroid metabolites by GC-MS. The fingerprints of 21 children with liver disease (L1) as assessed by sonographic steatosis (L1 L ), elevated alanine aminotransferases (L1 A ) or both (L1 AL ), were compared to 64 children without markers of liver disease (L0). The steroidal signature of the liver disease was generated as the difference in profiles of L1 against L0 groups. Results: L1 comparing to L0 presented higher fasting triglycerides (P = 0.004), insulin (P = 0.002), INS/GLU (P = 0.003), HOMA-IR (P = 0.002), GGTP (P = 0.006), AST/SGOT (P = 0.002), postprandial glucose (P = 0.001) and insulin (P = 0.011). L1 AL showed highest level of T-cholesterol and triglycerides (P = 0.029; P = 0.044). Fasting insulin, postprandial glucose, INS/GLU and HOMA-IR were highest in L1 L and L1 AL (P = 0.001; P = 0.017; P = 0.001; P = 0.001). The liver disease steroidal signature was marked by lower DHEA and its metabolites, higher glucocorticoids (mostly tetrahydrocortisone) and lower mineralocorticoid metabolites than L0. L1 patients showed higher 5α-reductase and 21-hydroxylase activity (the highest in L1 A and L1 AL ) and lower activity of 11βHSD1 than L0 (P = 0.041, P = 0.009, P = 0.019). Conclusions: The 'steroid metabolomic signature' of liver disease in childhood obesity provides a new approach to the diagnosis and further understanding of its metabolic consequences. It reflects the derangements of steroid metabolism in NAFLD that includes enhanced glucocorticoids and deranged androgens and mineralocorticoids.
Introduction
Nonsyndromic childhood obesity is associated with nonalcoholic fatty liver disease (NAFLD), a spectrum of conditions, ranging from steatosis to nonalcoholic steatohepatitis (NASH), and various degrees of fibrosis and cirrhosis (1) . NAFLD is regarded as the hepatic manifestation of the metabolic syndrome (2) . However, childhood obesity with no NAFLD is also complicated by the metabolic syndrome. Despite the growth of knowledge regarding obesity-related NAFLD in children, we still rely mostly on circulating levels of liver enzymes and ultrasonography imaging and some non-invasive tests (3, 4, 5, 6, 7) . Liver biopsy in children with suspected NAFLD is recommended only for 'those where the diagnosis is unclear, where there is possibility of multiple diagnoses or before starting therapy with potentially hepatotoxic medications' (8) .
The consequences of obesity-related NAFLD on liver metabolism are insufficiently understood (8) . As steroid hormones are partially catabolized and conjugated by liver enzymes, we have anticipated that NAFLD would have its metabolic impact on steroid metabolism.
Here, we utilized our previously reported concept, arguing that an individual's urinary steroid metabolite profile represents a subject's unique metabolic fingerprint and offers means of metabolomic phenotyping at the individual level (9, 10) . Thus, each individual has a unique 'steroidal fingerprint'. A cluster of similar 'steroidal fingerprints' related to a disease would be regarded as a 'steroid metabolomic disease signature' (10, 11) , which represents the impact of a disease in people who differ in their phenotypes or have other health problems. We have previously clustered steroidal fingerprints of children with nonsyndromic obesity into five clusters with distinctive steroidal signatures (11) .
Here, we analyzed the clinical data of a group of 85 patients with well-phenotyped nonsyndromic childhood obesity and defined those affected and those unaffected by NAFLD and/or elevated activities of liver enzymes. We generated steroidal disease signatures of the two groups and suggest that it might shed light on steroid-related metabolic sequelae of liver disease in childhood obesity.
Subjects and methods
Between March 2012 and August 2013, we examined a consecutive series of 117 obese Caucasian children and adolescents (BMI >97th centile). They were recruited from the patients referred to the Department of Pediatric Endocrinology, Medical University of Silesia, Katowice, Poland. After exclusion of younger participants (<8 years), syndromic obesity, chronic diseases, pharmacotherapy (also metformin) or precocious puberty, we included the remaining 85 patients (43 girls), aged 8.5-18.0 years (mean age 14.4, s.d. 2.33, median 14.5 years).
All patients underwent a clinical assessment and diagnostic procedures that included general physical examination, anthropometric measurements of height, weight, waist and hip circumference and puberty assessment, as previously described (11) . Morning fasting venous blood samples were collected to measure lipids, glucose (GLU), insulin (INS), TSH, fT4, cortisol and aminotransferases. Plasma total cholesterol (T Chol), high-density lipoprotein cholesterol (HDL-Chol) and triglyceride (TG) levels were analyzed enzymatically (Beckman Coulter). GLU and INS levels were also measured in an oral glucose tolerance test (OGTT, 1.75 g/kg, max 75 g). Enzymatic test (hexokinase method) was used for the quantitative determination of glucose (Beckman Coulter). INS was determined using a chemiluminescence immunoassay on Immulite 2000 analyzer (DPC, USA). 
Assessment of liver disease/NAFLD
Abdomen ultrasonography to evaluate the liver for hepatic steatosis features was performed with 5 MHz convex transducer (Logiq 5, GE Healthcare GmbH), according to the standards in pediatric population (12) . The evidence of hepatic steatosis by abdominal ultrasound (hepatic echogenicity increased above the echogenicity of the adjacent right renal cortex and increase in fine echoes of liver parenchyma compared with intrahepatic vessel borders (7, 13) ), and no causes for secondary hepatic fat accumulation, is defined here for NAFLD diagnosis (5, 7, 12) . Any markers of liver dysfunction 8:6
where defined as liver disease -L1 as compared to L0 -without markers of liver disease.
Gas chromatography-mass spectrometry (GC-MS) of urinary steroids
Steroid metabolites in 24-h urine samples were analyzed by quantitative targeted GC-MS (9, 10, 11) . Briefly, free and conjugated urinary steroids were extracted by solid phase extraction and conjugates were enzymatically hydrolyzed. After recovery of hydrolyzed steroids by solid phase extraction, known amounts of internal standards (5α-androstane-3α,17α-diol, stigmasterol) were added to each extract before formation of methyloximetrimethylsilyl ethers. GC was performed using an Optima-1 fused silica column (Macherey-Nagel, Dueren, Germany) housed in an Agilent Technologies 6890 series GC that was directly interfaced to an Agilent Technologies 5975 inert XL mass selective detector. After calibration, values for the excretion of individual steroids were determined by measuring the selected ion peak areas against the internal standard areas.
Steroid metabolites' ratios, as described in our previous paper (11) , were used to calculate the activity of the enzymes: 5α reductase (An/Et) (5αTHF/THF, 5αTHB/THB), 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) ((THF + αTHF)/THE), 3β-hydroxysteroid dehydrogenase-(3βHSD) ((THE + THF + αTHF)/P5T-17α) and 21-hydroxylase ((THE + THF + αTHF)/PT, (THE + THF + αTHF)/PO5α3α).
The study was conducted according to Helsinki declaration, and approved by the Ethics Committee of the Medical University of Silesia. Informed consent was obtained from each patient over age 16 years, a parent or a legal guardian, after full explanation of the purpose and nature of all procedures.
Statistical analysis and visualization of metabolomic data
Steroid metabolites quantities were z-transformed based on sex-and age-adjusted normal reference groups, as described elsewhere (11) . Per each of 31 z-transformed steroid metabolites and per each one of the groups L0, L1 and subgroups L1 A , L1 L , L1 AL , the median was computed. The standard R-function 'matplot' (https:// www.R-project.org/) (14) was used to depict the steroidal signatures of each subgroup as the difference between the above medians versus the median of L0 group (11) .
Clinical and chemical data as well as steroid metabolites' concentrations ratios of patients in each A group (Table 2B) .
Steroidal signature of liver disease
Obese patients of the L0 group presented higher midnight plasma cortisol concentration (P < 0.001) than the L1 group (Table 1B) . Comparing the z-transformed values of steroid metabolites, significantly higher tetrahydrocortisone (THE) concentration were found in L1 group (P = 0.046). 'Steroidal signature' of liver disease is presented as the difference between z-transformed concentrations of steroid metabolites in L0 and L1 patients (Fig. 1) . Liveraffected patients have shown significantly enhanced 5α-reductase and 21-hydroxylase activity and lower activity of 11βHSD1 than L0 subjects (Table 3) showed enhanced 5α-reductase activity (Table 4 ).
Figure 1
Steroidal signature of liver disease in childhood obesity: differences between z-transformed concentrations of steroid metabolites (androgens, glucocorticoids and mineralocorticoids) in liver diseases (L1) and with non-liver disease features (L0) patients. 
Discussion
Based on our previous definition of 'steroid metabolomic disease signature' by quantitative urinary steroidal GC-MS data (10, 11), here we define the steroidal signature of liver disease in nonsyndromic childhood obesity.
The results emphasize the fact that the clinical picture of obese children with liver disease is not different from that of obese children with no liver disease; they have comparable age, height, weight, BMI, waist and hip circumference and blood pressure. They have comparable serum TSH and 08:00 h cortisol, while their midnight cortisol is lower. Those with liver disease have higher circulating triglycerides, though their lipoproteins are comparable, as previously reported (15) . We confirm that obesity and insulin resistance play important roles in the development of NAFLD (16) . The insulin sensitivity indices of obese children with liver disease are marked by higher postprandial glucose and insulin, higher insulin/ glucose ratio and higher HOMA-IR (17) than those with no liver disease.
This complex 'steroidal signature' of liver disease reflects previously published single observations. The steroidal disease signature is marked by low urinary DHEA (18, 19) and its metabolites, higher glucocorticoid metabolites, due to increased glucocorticoid production rate (20) , and lower mineralocorticoid metabolites. It is characterized by derangement of the cortisol/ cortisone shuttle generated by 11β hydroxysteroid dehydrogenase (HSD) type 1 (20) , as is evident from the lower (THF + αTHF)/THE ratio, enhanced 3βHSD activity ((THE + THF + αTHF)/5PT-17α ratio) and enhanced 21-hydroxylase activity ((THE + THF + αTHF)/PT). These findings may suggest lesser hepatic recycling (reduction) of cortisone to cortisol in liver steatosis, which is compensated for by increased adrenal cortisol generation and further metabolic consequences resulting from higher glucocorticoids concentrations -this mechanism results in a model of a vicious circle.
Therefore, it is not surprising that higher tetrahydrocortisone concentration in L1 patients corresponds with unfavorable biochemical profile: higher triglycerides and insulin resistance. The clinical profile, however, defined by BMI z score or waist circumference, is not useful in the prediction of liver disease as well as other obesity complications.
A previous study focused on the measurement of circulating DHEAS and found low DHEAS in NASH patient. The authors assumed that this might have resulted from reduced sulphonation of DHEA (19) . Low sulphonation of steroids has also been found in a study in obese children (21) . A further important feature of the obesity-associated liver disease signature is the low urinary DHEA excretion rate and its metabolites. It was previously suggested that DHEA treatment reduced hepatic injury in experimental animals by inhibiting several inflammatory mediators such as tumor necrosis factor-α and macrophage mitogen inhibitory factor, and preventing the increase in serum ALT levels (22) . Thus, we speculate that DHEA might have a protective effect against hepatotoxicity. It has been shown that DHEA inhibits 11β-hydroxysteroid dehydrogenase-1 expression in liver and adipose tissues (23) -another component of the steroidal signature. The liver is also the site of greatest activity of 11βHSD (24) , and as such responds to liver disease with decreasing activity. Obesity per se tends to enhance 11βHSD-1 activity (25), but insulin resistance, a prominent manifestation of the metabolic syndrome in obesity and the group of children presented here, inhibits 11βHSD-1 activity (26) . Moreover, insulin resistance and the metabolic syndrome are involved in the development and progression of NAFLD (15) .
In conclusion, we present the 'disease signature' of liver disease in childhood obesity. We are aware of the limitations of our study as our results may be biased by observational cross-sectional character of the study and the relatively small number of participants in subgroups with liver dysfunction. Moreover, we did not quantify the ultrasonographic steatosis, other than visually. However, our findings suggest a new approach to the diagnosis and further understanding of the metabolic consequences of liver disease as part of the metabolic syndrome of obesity. They reflect the derangements of steroid metabolism in NAFLD that includes enhanced glucocorticoid production and deranged androgens and mineralocorticoids and suggests a protective effect of DHEA on the liver in childhood obesity. Knowledge of these sequels may provide ways for personalized medicine in obese children with liver disease. Future prospective intervention study is also needed to verify if obtained findings are only reversible consequences of obesity or whether they reflect non-modifiable individual genetic predisposition. 
